# Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

> **NCT03593655** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 247 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DEVICE:** Dapivirine vaginal ring
- **DRUG:** FTC/TDF

## Key facts

- **NCT ID:** NCT03593655
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2021-09-09
- **Final completion:** 2021-09-09
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593655, "Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03593655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*